AI and the Pharmaceutical Industry — 2026-10-25 (Sun)

Overview

Today's central item is the $237M Series E for Pathos AI (valuation $3B), led by Bristol Myers Squibb (BMS). The company is also involved in a neurology data partnership with Tempus AI, which suggests BMS is tying up AI drug discovery companies on both funding and data. A $400 M deal between Astellas Pharma and AI Proteins is also on the list, but it is a drug discovery collaboration, not a story about deployment or operations.

By Category

Drug discovery: Warp Sciences launched with $215 Million in funding. It is billed as "bringing AI drug discovery into the lab," which reads as a move toward a design that runs computation and experimental systems together. The headline does not reveal the investors or the technology base.

Company-wide AI infrastructure and governance: The relevant items are the investment in Pathos AI, the Tempus AI data partnership, and Astellas Pharma's contract with AI Proteins. Tempus AI also signed a multi-year agreement with BMS to license multimodal oncology data. The Tricog Health item and the Sanofi/OMRON Healthcare item do not show amounts or contract terms in their headlines, so their placement is on hold.

Reading the Investment Map

The money flows in three directions. The first is equity investment in AI drug discovery companies: Warp Sciences' $215 Million and Pathos AI's $237M (valuation about $3B). The $3B is the company's valuation, not the amount invested. The second is drug discovery collaboration: the $400 M deal between Astellas Pharma and AI Proteins. From the headline alone, it is unclear whether this is a confirmed amount or a total that includes milestones. The third is data acquisition: the neurology partnership between Tempus AI and Pathos AI is worth up to $55 Million (a ceiling, not a confirmed amount). No amount has been reported for the oncology data agreement between BMS and Tempus AI.

What to Watch

Whether the breakdown of the $400 M Astellas Pharma and AI Proteins deal is disclosed (payments at signing versus payments tied to results). 2. Because BMS is involved with both Pathos AI and Tempus AI, how the neurology partnership expands next.